专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO1991009594A1 SIGMA RECEPTOR LIGANDS AND THE USE THEREOF 审中-公开
标题翻译： SIGMA受体配体及其用途
公开(公告)号：WO1991009594A1
公开(公告)日：1991-07-11
申请号：PCT/US1990007653
申请日：1990-12-28
申请人： VIRGINIA COMMONWEALTH UNIVERSITY , GLENNON, Richard, A.
发明人： VIRGINIA COMMONWEALTH UNIVERSITY
IPC分类号： A61K31/085
CPC分类号： C07D209/48 , A61K31/135 , A61K31/215 , A61K31/40 , A61K31/435 , A61K31/44 , A61K31/445 , A61K31/495 , A61K31/505 , A61K31/535 , A61K31/55 , C07C211/08 , C07C211/17 , C07C211/27 , C07C211/28 , C07C211/29 , C07C211/30 , C07C211/42 , C07C215/52 , C07C217/16 , C07C217/60 , C07C219/10 , C07C219/12 , C07C225/16 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07C2602/10 , C07C2602/12 , C07C2603/18 , C07D207/12 , C07D211/14 , C07D211/46 , C07D211/52 , C07D211/70 , C07D223/16 , C07D239/42 , C07D265/30 , C07D295/03 , C07D295/033 , C07D295/073 , C07D295/096 , C07D295/108 , C07D295/192 , C07D317/58 , C07D471/08
摘要： The invention relates to methods for the treatment of schizophrenia or other psychoses by administering a pharmaceutical composition comprising an effective amount of certain sigma receptor ligands to a patient in need of such treatment. The invention further relates to novel sigma receptor ligands having high binding to the sigma receptor and pharmaceutical compositions thereof.
摘要翻译：本发明涉及通过向需要这种治疗的患者施用包含有效量的某些σ受体配体的药物组合物来治疗精神分裂症或其它精神病的方法。本发明还涉及具有与σ受体高度结合的新型σ受体配体及其药物组合物。

2. 发明申请

WO1997004780A3 PAIN-ALLEVIATING DRUG COMPOSITION AND METHOD FOR ALLEVIATING PAIN 审中-公开
公开(公告)号：WO1997004780A3
公开(公告)日：1997-02-13
申请号：PCT/US1996012597
申请日：1996-07-31
申请人： VIRGINIA COMMONWEALTH UNIVERSITY
发明人： VIRGINIA COMMONWEALTH UNIVERSITY , MAYER, David, J. , PRICE, Donald, D. , MAO, Jianren , LYLE, John, W.
IPC分类号： A61K31/485

3. 发明申请

WO1992017494A1 ASSAY FOR EQUINE INFECTIOUS ANEMIA VIRUS 审中-公开
标题翻译： EQUINE INTEMIA ANEMIA VIRUS的测定
公开(公告)号：WO1992017494A1
公开(公告)日：1992-10-15
申请号：PCT/US1991002287
申请日：1991-04-08
申请人： VIRGINIA COMMONWEALTH UNIVERSITY
发明人： VIRGINIA COMMONWEALTH UNIVERSITY , PETERSON, Darrell , HU, Peisheng
IPC分类号： C07K07/10
CPC分类号： C07K14/005 , C12N2740/15022
摘要： The present invention is directed toward the use of a synthetic peptide as the antigen in an immunoassay for the detection of antibodies against the equine infectious anemia virus in the serum of horses. The synthetic peptide corresponds to the amino acid sequence of an antigenic portion of the GP-45 envelope protein of the equine infectious anemia virus. The immunoassay may be a direct second antibody immunoassay, a one or two step sandwich immunoassay, or a competitive immunoassay.
摘要翻译：本发明涉及在免疫测定中使用合成肽作为抗原来检测马血清中针对马传染性贫血病毒的抗体。合成肽对应于马感染性贫血病毒的GP-45包膜蛋白的抗原部分的氨基酸序列。免疫测定可以是直接的第二抗体免疫测定，一步或两步夹心免疫测定或竞争性免疫测定。

4. 发明申请

WO1997042988A2 METHOD AND APPARATUS AND TREATMENT OF PATIENTS BY LOWERING INTRA-ABDOMINAL PRESSURE 审中-公开
标题翻译：方法和装置，通过降低腹腔压力治疗患者
公开(公告)号：WO1997042988A2
公开(公告)日：1997-11-20
申请号：PCT/US1997007628
申请日：1997-05-07
申请人： VIRGINIA COMMONWEALTH UNIVERSITY
发明人： VIRGINIA COMMONWEALTH UNIVERSITY , SUGERMAN, Harvey, J.
IPC分类号： A61M00/00
CPC分类号： A61H9/005 , A61H2205/083
摘要： An abdominal decompression apparatus is used to treat a variety of disorders including acute abdominal compartment syndrome, increased intra-abdominal pressure related morbidity in severely obese persons, and pre-eclampsia and other complications associated with increased abdominal pressure in pregnancy. The abdominal decompression apparatus is worn for an extended period of time (e.g., 6-12 hours at a time), with relatively low levels of pressure being applied (e.g., -20 to -45 mm Hg). Preferably, abdominal decompression is performed on a continuous basis with the final pressure being gradually achieved. In a preferred embodiment, the patient's urinary bladder pressure is used as a measure of intra-abdominal pressure. The sensed urinary bladder pressure can be used to gauge the effectiveness of treatment as well as to control parameters of the abdominal decompression device (e.g., time of use, pressure utilized, etc.).
摘要翻译：腹部减压装置用于治疗各种疾病，包括急性腹腔综合征，严重肥胖者腹内压升高相关发病率，以及与妊娠期腹压增加相关的先兆子痫和其他并发症。腹部减压装置长时间佩戴（例如每次6-12小时），施加相对低的压力水平（例如，-20至-45mm Hg）。优选地，在逐渐实现最终压力的情况下，连续进行腹部减压。在优选实施例中，将患者的膀胱压力用作腹内压力的量度。感测的膀胱压力可用于测量治疗的有效性以及控制腹部减压装置的参数（例如，使用时间，使用的压力等）。

5. 发明申请

WO1995027083A1 METHOD FOR DIAGNOSING CHRONIC HEPATITIS B VIRUS INFECTION 审中-公开
标题翻译：用于诊断慢性乙型肝炎病毒感染的方法
公开(公告)号：WO1995027083A1
公开(公告)日：1995-10-12
申请号：PCT/US1995004061
申请日：1995-03-31
申请人： THE SCRIPPS RESEARCH INSTITUTE , MAX-PLANCK-GESELLSCHAFT , VIRGINIA COMMONWEALTH UNIVERSITY
发明人： THE SCRIPPS RESEARCH INSTITUTE , MAX-PLANCK-GESELLSCHAFT , VIRGINIA COMMONWEALTH UNIVERSITY , MILICH, David, R. , MARUYAMA, Toshiyuki , SCHODEL, Florian , PETERSON, Darrell
IPC分类号： C12Q01/70
CPC分类号： G01N33/5762 , Y10S436/82
摘要： Human antibodies that bind to woodchuck hepatitis virus core antigen are elevated in chronic hepatitis B patients in comparison to acute hepatitis B patients. Immunoassays for detection of the level of anti-WHV core antigen antibodies is used to distinguish chronic from acute hepatitis B patients.
摘要翻译：与急性乙型肝炎患者相比，慢性乙型肝炎患者中与土拨鼠肝炎病毒核心抗原结合的人抗体升高。用于检测抗WHV核心抗原抗体水平的免疫测定用于区分慢性和急性乙型肝炎患者。

6. 发明申请

WO1995000131A1 SIGMA RECEPTOR LIGANDS AND THE USE THEREOF 审中-公开
标题翻译： SIGMA受体配体及其用途
公开(公告)号：WO1995000131A1
公开(公告)日：1995-01-05
申请号：PCT/US1994007121
申请日：1994-06-23
申请人： CAMBRIDGE NEUROSCIENCE, INCORPORATED , VIRGINIA COMMONWEALTH UNIVERSITY , GLENNON, Richard, A. , FISCHER, James, B.
发明人： CAMBRIDGE NEUROSCIENCE, INCORPORATED , VIRGINIA COMMONWEALTH UNIVERSITY
IPC分类号： A61K31/135
CPC分类号： C07D317/58 , C07C211/27 , C07C211/28 , C07C211/29 , C07C211/42 , C07C215/30 , C07C219/10 , C07C219/12 , C07C225/16 , C07C2603/18 , C07D211/14 , C07D211/18 , C07D211/22 , C07D211/32 , C07D211/52 , C07D211/70 , C07D295/03 , C07D295/033 , C07D295/073 , C07D295/096 , C07D295/104 , C07D295/13
摘要： The invention relates to methods for the treatment of central nervous system disorders, neurological disorders, gastrointestinal disorders, drug abuse, angina, migraine, hypertension and depression by administering a pharmaceutical composition comprising an effective amount of certain sigma receptor ligands to a patient in need of such treatment. The invention further relates to novel sigma receptor ligands having high binding to the sigma receptor and pharmaceutical compositions thereof.
摘要翻译：本发明涉及通过向需要治疗的患者施用包含有效量的某些σ受体配体的药物组合物来治疗中枢神经系统疾病，神经障碍，胃肠道疾病，药物滥用，心绞痛，偏头痛，高血压和抑郁症的方法这样的治疗。本发明还涉及具有与σ受体高度结合的新型σ受体配体及其药物组合物。

7. 发明申请

WO1993006836A1 VON WILLEBRAND FACTOR-SPECIFIC HEPARIN FRACTIONS 审中-公开
标题翻译： VON WILLEBRAND因子特异性HEPARIN分类
公开(公告)号：WO1993006836A1
公开(公告)日：1993-04-15
申请号：PCT/US1992008469
申请日：1992-10-05
申请人： VIRGINIA COMMONWEALTH UNIVERSITY , SOBEL, Michael , HARRIS, Robert, B.
发明人： VIRGINIA COMMONWEALTH UNIVERSITY
IPC分类号： A61K31/72
CPC分类号： C07K14/75 , A61K38/00
摘要： The invention provides heparin preparations of desired balance in anticoagulant activity and ability to inhibit vWF-mediated platelet adhesion/aggregation, and peptides useful in obtaining and identifying them. The invention thus provides a peptide of the formula: B1X2B3B4B5X6X7X8X9B10B11X12, wherein each B is independently a basic amino acid and each X is independently a nonbasic amino acid, wherein any of said peptides is optionally extended at the N- or C-terminus by moieties which do not interfere with the affinity of the peptide for heparin; and wherein one or more of the peptide linkages may optionally be replaced by an isosteric linkage, which peptide specifically binds a fraction of heparin preparations. The peptide is useful as a pharmaceutical composition to interfere with heparin inhibition of platelet aggregation or adhesion as well as to obtain fractions of heparin or derivatives thereof which are enhanced or depleted in ability to inhibit platelet aggregation and adhesion, dependent on von Willebrand Factor. The resulting heparin subfractions are useful pharmaceutically to regulate blood clotting that is dependent on platelet aggregation/adhesion.
摘要翻译：本发明提供了抗凝血活性和抑制vWF介导的血小板粘附/聚集的能力的期望平衡的肝素制剂，以及可用于获得和鉴定它们的肽。因此，本发明提供了下式的肽：B1X2B3B4B5X6X7X8X9B10B11X12，其中每个B独立地是碱性氨基酸，并且每个X独立地是非碱性氨基酸，其中所述肽中的任何一个在N-或C-末端任选地被部分延伸不妨碍肽对肝素的亲和力; 并且其中一个或多个肽键可以任选地被等位基团连接取代，所述肽特异性结合一部分肝素制剂。该肽可用作干扰肝素抑制血小板聚集或粘附的药物组合物，并且取决于冯维勒布兰德因子（Von Willebrand Factor），以获得增强或消除抑制血小板聚集和粘附的能力的肝素或其衍生物的部分。所得到的肝素亚组分在药学上可用于调节依赖于血小板聚集/粘附的血液凝固。

8. 发明申请

WO1991003512A1 CYTOPROTECTIVE FATTY MOIETY COMPOUNDS 审中-公开
标题翻译： CYPOPROTECTIVE FATTY MOIETY化合物
公开(公告)号：WO1991003512A1
公开(公告)日：1991-03-21
申请号：PCT/US1990004615
申请日：1990-08-16
申请人： VIRGINIA COMMONWEALTH UNIVERSITY , FRANSON, Richard, C. , REGELSON, William , OTTENBRITE, Raphael, M.
发明人： VIRGINIA COMMONWEALTH UNIVERSITY
IPC分类号： C08H03/00
CPC分类号： C11C3/00 , C07C69/732 , C07C219/08 , C07C233/20 , C07C233/38 , C07C233/49 , C07C309/14 , C07D207/16 , C07D307/24 , C07D333/38
摘要： Water or lipid soluble, pharmacologically active, antioxidant, anti-phospholipase compounds that are chemically defined. The compounds protect mammalian cells by inhibiting PLA2 and preventing oxidation. In particular, each compound has at least two fatty moieties and no active hydroxy group. The compound may also have at least one ionizable group, which may a carboxyl group, and each of the fatty moieties has from sixteen to twenty carbon atoms and at least one cis-unsaturated double bond.
摘要翻译：化学定义的水或脂溶性，药理活性，抗氧化剂，抗磷脂酶化合物。该化合物通过抑制PLA2并防止氧化来保护哺乳动物细胞。特别地，每种化合物具有至少两个脂肪部分并且不具有活性羟基。化合物还可以具有至少一个可以是羧基的可离子化基团，并且每个脂肪部分具有16至20个碳原子和至少一个顺式 - 不饱和双键。

9. 发明申请

WO1998012183A1 IMIDAZOLES WITH SEROTONIN RECEPTOR BINDING ACTIVITY 审中-公开
标题翻译：具有丝氨酸受体结合活性的咪唑烷
公开(公告)号：WO1998012183A1
公开(公告)日：1998-03-26
申请号：PCT/CA1997000680
申请日：1997-09-17
申请人： ALLELIX BIOPHARMACEUTICALS INC. , VIRGINIA COMMONWEALTH UNIVERSITY
发明人： ALLELIX BIOPHARMACEUTICALS INC. , VIRGINIA COMMONWEALTH UNIVERSITY , GLENNON, Richard, A. , LAW, Ho
IPC分类号： C07D233/54
CPC分类号： C07D233/56 , A61K31/4174 , C07D233/64
摘要： This invention relates to compounds having serotonin receptor binding activity, to pharmaceutical compositions containing them and to their medical use, particularly in the treatment of CNS conditions. Described herein are compounds which have general formula (I), wherein R is selected from H, C1-6alkyl and benzyl; R is selected from H and C1-6alkyl; R is selected from H and C1-6alkyl; R is selected from C1-6alkyl and halo; R is selected from H and OH; and salts, hydrates and solvates thereof. Also described is the use of these compounds as pharmaceuticals to treat indications where stimulation of subtypes of the serotonin receptor is implicated, such as migraine.
摘要翻译：本发明涉及具有5-羟色胺受体结合活性的化合物，含有它们的药物组合物及其医疗用途，特别是用于治疗CNS病症。本文描述的是具有通式（I）的化合物，其中R 1选自H，C 1-6烷基和苄基; R 2选自H和C1-6烷基; R 3选自H和C 1-6烷基; R 4选自C 1-6烷基和卤素; R 5选自H和OH; 及其盐，水合物和溶剂合物。还描述了这些化合物作为药物用于治疗涉及5-羟色胺受体的亚型的刺激的指征的用途，例如偏头痛。

10. 发明申请

WO1996006544A1 COMPOSITION FOR STRAIGHTENING AND PERMANENTLY WAVING KERATIN BASED MATERIALS 审中-公开
标题翻译：用于紧密和基于KERATIN的材料的组合物
公开(公告)号：WO1996006544A1
公开(公告)日：1996-03-07
申请号：PCT/US1995011069
申请日：1995-08-31
申请人： VIRGINIA COMMONWEALTH UNIVERSITY , OTTENBRITE, Raphael, M. , FADEEVA, Natasha
发明人： VIRGINIA COMMONWEALTH UNIVERSITY
IPC分类号： A45D07/04
CPC分类号： A61Q5/04 , A61K8/23 , A61K8/347 , A61K8/42 , A61K8/49
摘要： This invention is directed to a composition for straightening or permanently waving keratin based materials. In particular, this invention is directed to a composition for safely and effectively straightening or permanently waving hair without causing damage to the hair or leaving unwanted substances in the hair. More particularly, this composition relates to a composition for safely and effectively straightening or permanently waving difficult to process hair such as virgin untreated African-American, Asian, Mediterranean, or Latin hair.
摘要翻译：本发明涉及用于矫正或永久挥舞角蛋白的材料的组合物。特别地，本发明涉及一种用于安全有效地矫直或永久挥发头发而不会对毛发造成伤害或在毛发中留下不需要的物质的组合物。更具体地，该组合物涉及用于安全有效矫正或永久挥舞难以处理头发的组合物，例如未处理的未处理的非洲裔美国人，亚洲人，地中海或拉丁美洲毛发。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式